• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
POH
Click for more information
0.00% 0.0¢

PROGRESS 2023-2 TRUST - Announcements

Market Cap $0  ! watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
POHPOH Presents Transdermal Oxymorphone Data in USA05/05/14
POHEnrolments Completed for Phase 2 Acne Treatment TrialPRICE SENSITIVE23/04/14
POH2013 Annual Report and 2014 AGM Documentation17/04/14
POHWebcast Investment Presentation03/04/14
POHMarch 2014 NEWSLETTER17/03/14
POHAppendix 3X and Appendix 3Y Notices04/03/14
POHAppointment of Non-Executive Directors03/03/14
POHDecember 2013 Appendix 4E - Annual Financial ReportPRICE SENSITIVE28/02/14
POHNovartis Launches Voveran TPM Gel in IndiaPRICE SENSITIVE21/01/14
POHReconciliation of Non-Quoted Securities - Conditional Rights20/12/13
POHPhosphagenics - TPM in Dairy Feed Inclusion TechnologyPRICE SENSITIVE12/12/13
POHPOH Signs Further Deed of Settlement with Final PartiesPRICE SENSITIVE08/11/13
POHPhosphagenics Issues Proceedings Against Former Employee31/10/13
POHPhosphagenics Signs Deed of Settlement with Dr OgruPRICE SENSITIVE30/10/13
POHPhosphagenics' Oxymorphone Patch SuccessPRICE SENSITIVE24/10/13
POHOxymorphone Pain Relief Patch - Multi-Dose TrialPRICE SENSITIVE19/09/13
POHSeptember 2013 Newsletter10/09/13
POHReconciliation of Non-Quoted Securities04/09/13
POHPOH - TPM Drug Delivery Technology - PAINWeek 2013 in USA03/09/13
POHJune 2013 Appendix 4D Half Year Financial Report - AccountsPRICE SENSITIVE30/08/13
POHSale of Former CEO Shares05/08/13
POHPhosphagenics Pain Program UpdatePRICE SENSITIVE26/07/13
POHMisappropriations Investigation - Clarification25/07/13
POHAppendix 3Z Final Director's Interest Notice - Dr E Ogru24/07/13
POHInvoicing and Accounting Misappropriations InvestigationPRICE SENSITIVE24/07/13
POHResignation of Executive Director22/07/13
POHPhosphagenics to Launch Phase 2 Acne Treatment TrialPRICE SENSITIVE12/07/13
POHInvoicing and Accounting IrregularitiesPRICE SENSITIVE01/07/13
POHTrading HaltPRICE SENSITIVE28/06/13
POHAsia Biotech Invest 2013 Conference POH Presentation04/06/13
POHR & D Taxation IncentivePRICE SENSITIVE28/05/13
POHMay 2013 NEWSLETTER22/05/13
POHPhosphagenics AGM - Results of Meeting17/05/13
POHPhosphagenics - AGM - CEO Presentation17/05/13
POHPOH signs Agreement with Agricultural Research ServicePRICE SENSITIVE14/05/13
POHAppendix 3Y - Directors Change in Interest in Securities09/05/13
POHAppendix 3Y - Change in Interest in Securities07/05/13
POHAppendix 3Y - Change in Directors Interest Notice24/04/13
POHPOH Annual Report and AGM Documentation15/04/13
POHTPM/Diclofenac Gel - Themis in Supply Agmt with NovartisPRICE SENSITIVE15/04/13
POHAppendix 3Y - Change of Directors Interest Notice09/04/13
POHAppendix 3B - Reconciliation of Issued Securities08/04/13
POHAppendix 3Y Notice - Change Direcror's Interest08/04/13
POHOxymorphone Patch Meets Phase 1 End PointsPRICE SENSITIVE25/03/13
ACL +S&P DJ Indices Announces March Quarterly Rebalance01/03/13
POHPhosphagenics Further Expands Pain PortfolioPRICE SENSITIVE20/02/13
POHDecember 2012 Appendix 4E and Audited Financial ReportPRICE SENSITIVE19/02/13
POHOxycodone Patch UpdatePRICE SENSITIVE11/02/13
POHPOH - February 2013 Newsletter01/02/13
POHPOH Initiates Clinical Program with Oxymorphone TPM PatchPRICE SENSITIVE16/01/13
POHPhosphagenics to Supply Firming Cream to GNCPRICE SENSITIVE05/12/12
POHOxycodone Patch Update - Development and Product ExpansionPRICE SENSITIVE03/12/12
POHReconciliation - Non-Quoted Conditional Rights16/11/12
POHPOH in JV to Supply TPM Equine Supplements to Golbal MarketPRICE SENSITIVE31/10/12
POHPOH Licences TPM Platform to Indian Pharmaceutical CompanyPRICE SENSITIVE30/10/12
POHPresentation - Macquarrie Emerging Healthcare Conference10/10/12
POHSeptember 2012 Newsletter26/09/12
POHJune 2012 Half Yearly Report and Financial ReportPRICE SENSITIVE20/08/12
POHNeura Therapeutik Appointed as US Strategic AdvisorsPRICE SENSITIVE01/08/12
POHPhosphagenics to Develop Racehorse Supplements29/06/12
POHPOH - June 2012 Newsletter26/06/12
POHAustralian Life Sciences Investment Showcase in New York15/06/12
POHExpiry Non-Quoted ESOP Options - POHAQ07/06/12
POHPOH Further Refinements to Oxycodone Patch DesignPRICE SENSITIVE05/06/12
POHAnnual General Meeting - Results of Meeting24/05/12
POHPOH - AGM Chairman's Address and CEO Presentation24/05/12
POHCEO Presentation - Bell Potter Life Sciences Conference23/05/12
POHPhosphagenics Engages Labtec for Final Patch Design23/05/12
POHPOH adds David Jones as retail partner for Elixia productsPRICE SENSITIVE08/05/12
POHApp3B - Exercise Options - Reconcilation Non-listed security04/05/12
POHAnnual Report and Notice of AGM - Proxy Form20/04/12
POHPhosphagenics -Newsletter April 201211/04/12
POHPOH Signs License Agreement with Intas PharmaceuticalsPRICE SENSITIVE04/04/12
POHChange in substantial holding22/03/12
POHChange in substantial holding15/03/12
POHKorean Distribution Agreement for BioElixiaPRICE SENSITIVE15/03/12
POHChange in substantial holding06/03/12
POHPOH signs Agreement with Japanese Pharmaceutical CompanyPRICE SENSITIVE05/03/12
POHCeasing to be a substantial holder23/02/12
POHDecember 2011 Preliminary Final and Audited Financial ReportPRICE SENSITIVE21/02/12
POHChange in substantial holding17/02/12
POHDelivery of Further Positive Oxycodone Patch Trial ResultsPRICE SENSITIVE15/02/12
POHSubstantial Shareholding Notices - Form 605 and Form 60401/02/12
POHChange in substantial holding16/12/11
POHEquity Raising correction re issue price14/12/11
POHDecember 2011 eNewsletter and Placement of Shares14/12/11
POHGeneral Meeting Results and CEO Presentation09/12/11
POHChange of Director's Interest Notice (3)28/11/11
POHPivotal TPM-oxycodone Patch Trials BeginPRICE SENSITIVE21/11/11
POHShare Purchase Plan - Quotation os Shares and Refunds16/11/11
POHShare Purchase Plan Heavily Oversubscribed14/11/11
POHNotice of General Meeting and Proxy Form - 09 12 201103/11/11
POHPhosphagenics Licenses Diclofenac Gel for Indian MarketPRICE SENSITIVE02/11/11
POHSection 708A Cleansing Notice - placement of shares28/10/11
POHConfirmation of Placement of New Shares27/10/11
POHChange in substantial holding25/10/11
POHShare Purchase Plan documentation24/10/11
POHShare Purchase Plan - Notice under ASIC CO 09-42521/10/11
POHSuccessful $24.1m Capital Raising and $3m SPPPRICE SENSITIVE21/10/11
POHTrading haltPRICE SENSITIVE19/10/11
POHPOH Presents Transdermal Oxymorphone Data in USA
05/05/14
POHEnrolments Completed for Phase 2 Acne Treatment Trial
23/04/14PRICE SENSITIVE
POH2013 Annual Report and 2014 AGM Documentation
17/04/14
POHWebcast Investment Presentation
03/04/14
POHMarch 2014 NEWSLETTER
17/03/14
POHAppendix 3X and Appendix 3Y Notices
04/03/14
POHAppointment of Non-Executive Directors
03/03/14
POHDecember 2013 Appendix 4E - Annual Financial Report
28/02/14PRICE SENSITIVE
POHNovartis Launches Voveran TPM Gel in India
21/01/14PRICE SENSITIVE
POHReconciliation of Non-Quoted Securities - Conditional Rights
20/12/13
POHPhosphagenics - TPM in Dairy Feed Inclusion Technology
12/12/13PRICE SENSITIVE
POHPOH Signs Further Deed of Settlement with Final Parties
08/11/13PRICE SENSITIVE
POHPhosphagenics Issues Proceedings Against Former Employee
31/10/13
POHPhosphagenics Signs Deed of Settlement with Dr Ogru
30/10/13PRICE SENSITIVE
POHPhosphagenics' Oxymorphone Patch Success
24/10/13PRICE SENSITIVE
POHOxymorphone Pain Relief Patch - Multi-Dose Trial
19/09/13PRICE SENSITIVE
POHSeptember 2013 Newsletter
10/09/13
POHReconciliation of Non-Quoted Securities
04/09/13
POHPOH - TPM Drug Delivery Technology - PAINWeek 2013 in USA
03/09/13
POHJune 2013 Appendix 4D Half Year Financial Report - Accounts
30/08/13PRICE SENSITIVE
POHSale of Former CEO Shares
05/08/13
POHPhosphagenics Pain Program Update
26/07/13PRICE SENSITIVE
POHMisappropriations Investigation - Clarification
25/07/13
POHAppendix 3Z Final Director's Interest Notice - Dr E Ogru
24/07/13
POHInvoicing and Accounting Misappropriations Investigation
24/07/13PRICE SENSITIVE
POHResignation of Executive Director
22/07/13
POHPhosphagenics to Launch Phase 2 Acne Treatment Trial
12/07/13PRICE SENSITIVE
POHInvoicing and Accounting Irregularities
01/07/13PRICE SENSITIVE
POHTrading Halt
28/06/13PRICE SENSITIVE
POHAsia Biotech Invest 2013 Conference POH Presentation
04/06/13
POHR & D Taxation Incentive
28/05/13PRICE SENSITIVE
POHMay 2013 NEWSLETTER
22/05/13
POHPhosphagenics AGM - Results of Meeting
17/05/13
POHPhosphagenics - AGM - CEO Presentation
17/05/13
POHPOH signs Agreement with Agricultural Research Service
14/05/13PRICE SENSITIVE
POHAppendix 3Y - Directors Change in Interest in Securities
09/05/13
POHAppendix 3Y - Change in Interest in Securities
07/05/13
POHAppendix 3Y - Change in Directors Interest Notice
24/04/13
POHPOH Annual Report and AGM Documentation
15/04/13
POHTPM/Diclofenac Gel - Themis in Supply Agmt with Novartis
15/04/13PRICE SENSITIVE
POHAppendix 3Y - Change of Directors Interest Notice
09/04/13
POHAppendix 3B - Reconciliation of Issued Securities
08/04/13
POHAppendix 3Y Notice - Change Direcror's Interest
08/04/13
POHOxymorphone Patch Meets Phase 1 End Points
25/03/13PRICE SENSITIVE
ACL +S&P DJ Indices Announces March Quarterly Rebalance
01/03/13
POHPhosphagenics Further Expands Pain Portfolio
20/02/13PRICE SENSITIVE
POHDecember 2012 Appendix 4E and Audited Financial Report
19/02/13PRICE SENSITIVE
POHOxycodone Patch Update
11/02/13PRICE SENSITIVE
POHPOH - February 2013 Newsletter
01/02/13
POHPOH Initiates Clinical Program with Oxymorphone TPM Patch
16/01/13PRICE SENSITIVE
POHPhosphagenics to Supply Firming Cream to GNC
05/12/12PRICE SENSITIVE
POHOxycodone Patch Update - Development and Product Expansion
03/12/12PRICE SENSITIVE
POHReconciliation - Non-Quoted Conditional Rights
16/11/12
POHPOH in JV to Supply TPM Equine Supplements to Golbal Market
31/10/12PRICE SENSITIVE
POHPOH Licences TPM Platform to Indian Pharmaceutical Company
30/10/12PRICE SENSITIVE
POHPresentation - Macquarrie Emerging Healthcare Conference
10/10/12
POHSeptember 2012 Newsletter
26/09/12
POHJune 2012 Half Yearly Report and Financial Report
20/08/12PRICE SENSITIVE
POHNeura Therapeutik Appointed as US Strategic Advisors
01/08/12PRICE SENSITIVE
POHPhosphagenics to Develop Racehorse Supplements
29/06/12
POHPOH - June 2012 Newsletter
26/06/12
POHAustralian Life Sciences Investment Showcase in New York
15/06/12
POHExpiry Non-Quoted ESOP Options - POHAQ
07/06/12
POHPOH Further Refinements to Oxycodone Patch Design
05/06/12PRICE SENSITIVE
POHAnnual General Meeting - Results of Meeting
24/05/12
POHPOH - AGM Chairman's Address and CEO Presentation
24/05/12
POHCEO Presentation - Bell Potter Life Sciences Conference
23/05/12
POHPhosphagenics Engages Labtec for Final Patch Design
23/05/12
POHPOH adds David Jones as retail partner for Elixia products
08/05/12PRICE SENSITIVE
POHApp3B - Exercise Options - Reconcilation Non-listed security
04/05/12
POHAnnual Report and Notice of AGM - Proxy Form
20/04/12
POHPhosphagenics -Newsletter April 2012
11/04/12
POHPOH Signs License Agreement with Intas Pharmaceuticals
04/04/12PRICE SENSITIVE
POHChange in substantial holding
22/03/12
POHChange in substantial holding
15/03/12
POHKorean Distribution Agreement for BioElixia
15/03/12PRICE SENSITIVE
POHChange in substantial holding
06/03/12
POHPOH signs Agreement with Japanese Pharmaceutical Company
05/03/12PRICE SENSITIVE
POHCeasing to be a substantial holder
23/02/12
POHDecember 2011 Preliminary Final and Audited Financial Report
21/02/12PRICE SENSITIVE
POHChange in substantial holding
17/02/12
POHDelivery of Further Positive Oxycodone Patch Trial Results
15/02/12PRICE SENSITIVE
POHSubstantial Shareholding Notices - Form 605 and Form 604
01/02/12
POHChange in substantial holding
16/12/11
POHEquity Raising correction re issue price
14/12/11
POHDecember 2011 eNewsletter and Placement of Shares
14/12/11
POHGeneral Meeting Results and CEO Presentation
09/12/11
POHChange of Director's Interest Notice (3)
28/11/11
POHPivotal TPM-oxycodone Patch Trials Begin
21/11/11PRICE SENSITIVE
POHShare Purchase Plan - Quotation os Shares and Refunds
16/11/11
POHShare Purchase Plan Heavily Oversubscribed
14/11/11
POHNotice of General Meeting and Proxy Form - 09 12 2011
03/11/11
POHPhosphagenics Licenses Diclofenac Gel for Indian Market
02/11/11PRICE SENSITIVE
POHSection 708A Cleansing Notice - placement of shares
28/10/11
POHConfirmation of Placement of New Shares
27/10/11
POHChange in substantial holding
25/10/11
POHShare Purchase Plan documentation
24/10/11
POHShare Purchase Plan - Notice under ASIC CO 09-425
21/10/11
POHSuccessful $24.1m Capital Raising and $3m SPP
21/10/11PRICE SENSITIVE
POHTrading halt
19/10/11PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.0¢ 		Change
0.000(0.00%) 		Mkt cap ! n/a
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
POH (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.